CD33 and acute myeloid leukemia: Subsequent data on the administration of GO using a fractionated-dosing schedule demonstrated both safety and efficacy, which resulted in its reapproval in combination with intensive chemotherapy in CD33+ AML in adults in the frontline setting in 2017, following the crucial French ALFA-0701 study [33].